secwatch.observer — SEC 8-K summary
======================================

Issuer:     HARROW, INC. (HROW)
CIK:        0001360214
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001493152-24-045283
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harrow Q3 revenue up 44% to $49.3M; reaffirms FY2024 guidance above $180M
-------------------------------------------------------------------------

- GAAP net loss of $4.2M; Adjusted EBITDA $8.8M; core gross margin improved to 80%.
- VEVYE prescriptions up 55% QoQ; IHEEZO unit demand up 15% QoQ; TRIESENCE relaunched in October.
- Cash $72.6M; $37M milestone payment for TRIESENCE funded by $30M Oaktree drawdown.
- First major Medicare Part D win for VEVYE with Express Scripts, Cigna, Kaiser, CVS Caremark.
- FY2024 revenue guidance reaffirmed at >$180M; Q4 expected to significantly outpace Q3.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1360214/000149315224045283/0001493152-24-045283-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1360214/000149315224045283/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-045283

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer